Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* moderate to severe hypertension~* 3 additional risk factors such as age \> 55 (male), \> 65 female, smoker, type 2 diabetes, obesity, cardiovascular disease, congestive heart failure, chronic kidney disease,~* ability to give informed consent~Exclusion Criteria:~* secondary or malignant hypertension~* contraindication to any of the study drugs~* Creatinine clearance level \<40ml/min~* treatment with more than 3 antihypertensive drugs~* Myocardial infarction, percutaneous transluminal coronary angioplasty, cardiac bypass surgery \< 6 month prior to start of the study,~* unstable angina pectoris,~* stroke, transient ischemic attack \< 3 months prior to start,~* Congestive heart failure NYHA II-IV,~* clinically relevant concomitant diseases,~* alcohol or drug abuse,~* pregnancy or women of childbearing potential without contraceptive precaution,

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Perindopril+amlodipine (Type: ACTIVE_COMPARATOR): None
- Olmesartan/amlodipine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).